Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cameron

Showing results (391-400 of 481) with videos related to

Pageof 49
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 8, 2016
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationDavid Miles, David Cameron, Igor Bondarenko, et al.
British Journal of Cancer|March 23, 2019
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomesHervé Bonnefoi, Gaetan MacGrogan, Coralie Poncet, et al.
Frontiers in Oncology|February 17, 2023
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTOSerena Di Cosimo, Chiara M Ciniselli, Sara Pizzamiglio, et al.
The Lancet. Oncology|November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trialGalina Velikova, James P Morden, Joanne S Haviland, et al.
Anticancer Research|February 4, 2019
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA TrialAmir Sonnenblick, Andrew Bailey, Beatrice Uziely, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 2008
Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearanceAnura P Jayasooriya, Michael L Mathai, Lesley L Walker, et al.
Journal of Nephrology|November 7, 2024
Improving the sustainability and quality of kidney health care through life cycle assessments, quality improvement, education and technical innovations: the KitNewCare approachBrett Duane, Ingeborg Steinbach, Rachel Stancliffe, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent seriesAndrew R Green, Daniele Soria, Jacqueline Stephen, et al.
Cancer Letters|April 23, 2013
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53Shelly Seward, Assaad Semaan, Aamer M Qazi, et al.
Translational Psychiatry|February 3, 2023
Maternal preconception circulating blood biomarker mixtures, child behavioural symptom scores and the potential mediating role of neonatal brain microstructure: the S-PRESTO cohortJian Huang, Ai Peng Tan, Evelyn Law, et al.
Pageof 49

Showing results (391-400 of 481) with videos related to

Sort By:
Pageof 49
European Journal of Cancer (Oxford, England : 1990)|November 8, 2016
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationDavid Miles, David Cameron, Igor Bondarenko, et al.
British Journal of Cancer|March 23, 2019
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomesHervé Bonnefoi, Gaetan MacGrogan, Coralie Poncet, et al.
Frontiers in Oncology|February 17, 2023
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTOSerena Di Cosimo, Chiara M Ciniselli, Sara Pizzamiglio, et al.
The Lancet. Oncology|November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trialGalina Velikova, James P Morden, Joanne S Haviland, et al.
Anticancer Research|February 4, 2019
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA TrialAmir Sonnenblick, Andrew Bailey, Beatrice Uziely, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 2008
Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearanceAnura P Jayasooriya, Michael L Mathai, Lesley L Walker, et al.
Journal of Nephrology|November 7, 2024
Improving the sustainability and quality of kidney health care through life cycle assessments, quality improvement, education and technical innovations: the KitNewCare approachBrett Duane, Ingeborg Steinbach, Rachel Stancliffe, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent seriesAndrew R Green, Daniele Soria, Jacqueline Stephen, et al.
Cancer Letters|April 23, 2013
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53Shelly Seward, Assaad Semaan, Aamer M Qazi, et al.
Translational Psychiatry|February 3, 2023
Maternal preconception circulating blood biomarker mixtures, child behavioural symptom scores and the potential mediating role of neonatal brain microstructure: the S-PRESTO cohortJian Huang, Ai Peng Tan, Evelyn Law, et al.
Pageof 49